GlassScriptPhysician profile
Sarah Hanson
NPI 1225813074
$1,877.13
in general payments reported to CMS, 2019-2025
24 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $143 · 2024: $690 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $345.61 | 2024-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $187.20 | 2023-2025 | Lifevest |
| Heartflow, INC. | $157.50 | 2025 | |
| Amgen INC. | $145.48 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Boston Scientific Corporation | $117.06 | 2025 | General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| E.R. Squibb & Sons, L.L.C. | $107.03 | 2025 | Eliquis, Camzyos |
| Kestra Medical Technology Services, INC. | $89.68 | 2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $85.64 | 2025 | |
| Glaxosmithkline, LLC. | $74.65 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Bioventus LLC | $72.88 | 2024 | Exogen Ultrasound Bone Healing System |
| Pfizer INC. | $63.92 | 2024-2025 | |
| Eisai INC. | $63.50 | 2024 | |
| Novo Nordisk INC | $61.28 | 2024 | Rybelsus, Ozempic |
| Abbvie INC. | $44.98 | 2024-2025 | |
| Fidia Pharma USA INC. | $39.82 | 2024 | Hymovis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $38.75 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $30.74 | 2024 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $30.26 | 2024-2025 | Verquvo, Gardasil 9, Capvaxive |
| Abbott Laboratories | $24.94 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.63 | 2024 | Jardiance |
| Astellas Pharma US INC | $22.22 | 2024 | Veozah |
| Medtronic, INC. | $20.72 | 2025 | Venaseal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.50 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $13.14 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.